(Q43813366)

27 November 2017

0 references

Adrenal suppression with inhaled corticosteroids (English)

1 reference

27 November 2017

B J Lipworth

1

1 reference

27 November 2017

publication date

1 November 2001

1 reference

Annals of Allergy, Asthma & Immunology

27 November 2017

published in

1 reference

27 November 2017

volume

87

1 reference

27 November 2017

issue

5

1 reference

27 November 2017

page(s)

359-361

1 reference

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Measuring the systemic effects of inhaled beclomethasone: timed morning urine collections compared with 24 hour specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Safety of inhaled and intranasal corticosteroids: lessons for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered-dose inhaler.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Relative effects of exogenous inhaled corticosteroids on diurnal cortisol secretion

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

In vitro properties of pressurized metered dose inhalers with and without spacer devices

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Differences in lung bioavailability between different propellants for fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962914-6

7 January 2021

10.1016/S1081-1206(10)62914-6

Identifiers

DOI

1 reference

27 November 2017

1 reference